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ABSTRACT
Objective: To assess the overall population impact of
primary prevention strategies (promotion of healthy
lifestyles, prevention of smoking and use of vascular
risk drug therapy) of coronary disease in Spain.
Design: Ecological time series analysis, 1982–2009.
Setting: All public and private hospitals in Spain.
Participants: General population.
Outcome: Incident coronary disease hospitalisation as
derived from official hospital discharge data.
Methods: Annual hospitalisation rates were modelled
according to nationwide use of statins,
antihypertensive, antidiabetic and antiplatelet drugs,
and prevalences of smoking, obesity and overweight.
Additive generalised models and mixed Poisson
regression models were used for the purpose, taking
year as the random-effect variable and adjusting for
age, sex, prevalence of vascular risk factors and the
number of hospital beds in intensive and coronary care
units.
Results: Across 28 years and 671.5 million person-
years of observation, there were 2 986 834
hospitalisations due to coronary disease; of these,
1 441 980 (48.28%) were classified as incident.
Hospitalisation rates increased from 1982 to 1996,
with an inflection point in 1997 and a subsequent 52%
decrease until 2009. Prevalences of smoking, obesity,
overweight and use of vascular risk drug therapy were
significantly associated with hospitalisation rates
(p<0.001): incidence rates ratios (95% CI) for the
fourth versus the first quartile were 1.46 (1.42 to
1.50), 1.80 (1.78 to 1.83), 1.58 (1.55 to 1.60) and
0.57 (0.51 to 0.63), respectively. These variables
accounted for 92% of interannual variability.
Conclusions: After decades of continuous rises,
hospitalisation due to incident ischaemic heart disease
has been cut by half, an achievement associated with
the decline in smoking and the increase in vascular
risk drug therapy. These results indicate that these two
primary prevention strategies have been effective at a
population level, thanks to an appropriate balance
between financial and health goals, something that
should be left intact despite the current economic
crisis. Future strategies ought to lay special stress on
excessive body weight prevention.
INTRODUCTION
Ischaemic heart disease (IHD) is a severe
disease, is lethal in its acute form in 20–30%
of cases1—indeed, it is the leading cause of
death in men and the second leading cause
of death in women in Spain2— and is chron-
ically incapacitating in a great proportion of
survivors. Its frequency in the Spanish popu-
lation is high, with population incidence
being estimated at 207 and 45/100 000 in
Strengths and limitations of this study
▪ The study shows that the decline in coronary
disease in Spain was associated with the expo-
nential increase in pharmacological treatment of
vascular risk, together with the decline in active
smoking that followed the strong interventions
against tobacco use implemented in mid-1990s
and late 1990s. This decrease in ischaemic heart
disease hospitalisation rates could have been
even greater, had it not been for the frequency of
excessive weight, which not only failed to
decline but actually rose.
▪ The exposure–effect associations found: (1) are
of great magnitude; (2) show a strong dose–
response relationship; (3) show a correct tem-
porality; (4) are biologically plausible and (5) are
consistent with similar studies in other countries,
with trends in other tobacco-related diseases and
with the increase in the rates of detection, treat-
ment and control of vascular risk factors in
Spain.
▪ The results are relevant as some of these mea-
sures (ie, broad use of statins in general popula-
tion) are still controversial. Moreover, the results
may substantially affect public health policy,
especially in a context of financial crisis.
▪ This is an ecological study based on health indi-
cators and targeted at the assessment of public
health; its results should not be interpreted as
outcomes of intervention trials, even though they
may nuance the latter insofar as they provide an
illustration of their external validity.
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men and women, respectively, and hospitalisation
140 000 cases annually.3 Consequently, this situation
became a public health priority and the target of spe-
ciﬁc health-planning strategies at a national level.4
The main vascular risk factors (excessive body weight,
smoking habit, hypercholesterolaemia, arterial hyperten-
sion and diabetes mellitus) can be modiﬁed by changes
in lifestyle or therapeutic interventions. In recent years,
cardiovascular disease prevention has, therefore, been
the focus of a major collective effort, in which health
professionals as well as scientiﬁc societies, the pharma-
ceutical industry and health administrations have all
taken part. The pillars of IHD prevention have been pre-
vention of smoking, promotion of healthy lifestyles, and
detection, treatment and medical control of arterial
hypertension, hypercholesterolaemia, diabetes mellitus
and platelet aggregation in high-risk patients.4 5 These
strategies have been generally implemented throughout
the Spanish National Health System, as a result of
recommendations made by the respective health author-
ities,4 prevention guidelines drawn up by experts and sci-
entiﬁc societies, both domestic and international,5–7 and
the development of risk functions which not only enable
patients to be stratiﬁed according to their individual cor-
onary risk, estimated on the basis of vascular risk factors
taken jointly,8 9 but also serve as a guide when it comes
to making therapeutic decisions about controlling vascu-
lar risk.
The promotion of healthy habits has speciﬁcally
centred on diet and physical exercise.10 Prevalence of
obesity and overweight is regarded as an indicator of
inadequate diet and physical activity.4 11 With respect to
smoking, the impact of antismoking interventions on
coronary risk has been comprehensively described at an
individual and a population level. Hence, assessment of
epidemiological antismoking legislation in a number of
countries has shown its effectiveness in terms of IHD
mortality and morbidity.12 13 Finally, the use of cardiovas-
cular disease prevention drug therapy in healthy persons
has demonstrated its effectiveness at an individual level
in many clinical trials, though it is not known whether
this effectiveness has been reﬂected at a population
level, that is, its epidemiological impact. Clinical trials
are conducted under controlled experimental condi-
tions and the patients included are selected on the basis
of strict inclusion and exclusion criteria. Consequently,
such studies do not represent the general population
and their results may possibly not be seen at a popula-
tion level (external validity).14
To our knowledge, there is no study that has assessed
the joint impact of these cardiovascular disease preven-
tion measures on IHD incidence. Epidemiological
studies undertaken in different countries,15–20 including
Spain,21 have linked the decrease in cardiovascular and
IHD mortality to the decline in population levels of vas-
cular risk factors. In Spain, 50% of the reduction in cor-
onary mortality is estimated to be due to changes in risk
factors, essentially total cholesterol (close on 31% of the
fall in mortality) and systolic blood pressure (15%).21
Most of these studies have, however, been based on
IMPACT methodology,17 18 which was designed to assess
changes in mortality but has not been adapted to the
task of assessing morbidity. Recent studies in the
USA,22 23 Italy24 and Australia25 have reported a
decrease in IHD-related hospital morbidity, which was
linked to antismoking legislation and the use of cardio-
protective medication, though these associations were
not statistically proved. Finally, a recent population-based
observational study in Israel26 assessed the effect of con-
tinued use of statins on the incidence of acute infarction
and coronary revascularisation but did not consider the
effect of use of antihypertensive, antiplatelet or antidia-
betic drugs.
Accordingly, the aim of this study was to describe the
time trend in hospital incident-IHD-related morbidity
rates and assess the impact of smoking prevention, pro-
motion of healthy lifestyles and the use of cardiovascular
disease prevention drug therapy, using the following as
indicators: population prevalence of smoking; preva-
lence of obesity and overweight and use of statins and
antihypertensive, antiplatelet and antidiabetic drugs.
METHODS
We conducted an epidemiological assessment study on
the impact of preventive measures, using regression ana-
lysis and time-series modelling and, for study purposes,
included the total Spanish population over 29 years of
age. The period considered in the description of the
time series was 1982–2009, avoiding the years preceding
the entry into force of the International Classiﬁcation of
Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM). In the analysis of related factors, the series
was restricted to the period 1996–2006, since this was
the period for which data on all the explanatory vari-
ables were available.
Principal and secondary variables
Data sources
The outcome variable was frequency of hospitalisation
due to incident IHD (ICD-9-CM codes 410–414, with
four digits), expressed in descriptive analyses in the
form of annual age-adjusted rates according to the
Standard European Population. Data on hospital dis-
charges due to this cause were drawn from anonymised
MBDS microﬁches (Minimum Basic Data Set/Conjunto
Mínimo Básico de Datos, the ofﬁcial nation-wide adminis-
trative and statistical database which includes clinical
and demographic data on every hospital discharge,
obtained from the pertinent medical records), and were
completed with a patient discharge sample from some
private hospitals that were not included in the MBDS.
The ﬁches were supplied by the National Statistics
Institute (NSI) (Instituto Nacional de Estadística) under a
data loan agreement containing an undertaking of con-
ﬁdentiality and respect for statistical secrecy. Population
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data for calculating the rates for each year, sex and age
group were obtained from NSI intercensal estimates.
The age strata were 5-year age groups starting from 30 to
85 and older.
An incident event was deﬁned as that in which the fol-
lowing two conditions were fulﬁlled: (1) diagnosis at dis-
charge of acute IHD, acute myocardial infarction,
intermediate coronary syndrome (unstable angina) or
angina pectoris (ICD 410, 411 or 413) and (2) ﬁrst
admission due to IHD, as shown by a check for duplicate
entries based on the ﬁelds, ‘sex’, ‘date of birth’ and
‘province of residence’. Events for which control for
duplicates could not be performed for lack of any
record of the patient’s complete date of birth (n=91 176,
3.1%) were excluded.
The method used to control for duplicates was vali-
dated by comparing the results against data on 30 205
hospitalisations in eight cities for which patient identiﬁ-
cation codes were available, yielding a sensitivity of
97.88% and speciﬁcity of 88.73. The distribution by
age, sex and diagnostic category of this validation
sample did not differ from that of the study
population.
The variables considered as potentially explanatory of
the trend in IHD hospitalisation rates in the population
were:
Use of statins (atorvastatin, cerivastatin, ﬂuvastatin,
lovastatin, pravastatin and simvastatin);
Use of antihypertensive drugs (angiotensin II receptor
antagonists, ACE inhibitors, β-blockers, diuretics,
calcium channel blockers and others);
Use of platelet aggregation inhibitors (aspirin, carbasalate,
clopidogrel, dipyridamol, citazol, ticlopidine and triﬂusal);
Use of antidiabetic drugs (insulins, biguanides, sulfo-
nylureas, α-glucosidase inhibitors, thiazolidinediones
and combinations of these).
The use of these drugs was expressed in Deﬁned Daily
Doses (DDDs) per 1000 inhabitants per day (DHDs),
for the period 1996–2006. These data were drawn
from reports issued by the Spanish Medications &
Health Products Agency on the basis of data on
packages dispensed under and charged to the
National Health System.27 The methodology used is
described in detail in these publications. DHDs
divided by 10 were introduced into the models, with
the estimators having to be interpreted as the effect
for every increase of 10 units in DHD.
Prevalence, with a breakdown by year, sex and age, of
smoking, overweight, obesity, arterial hypertension,
hypercholesterolaemia and diabetes mellitus obtained
from self-report data in the 1987,1993, 1995, 1997,
2001, 2003 and 2006 National Health Surveys,28 with
data for the intermediate years being estimated by
means of linear interpolation of data for the pivotal
years.
Number of physically available hospital beds in inten-
sive care and coronary care units per 1000
inhabitants.28
Data analysis
Weightings speciﬁed by the NSI were used for the calcu-
lation of the number of cases. In descriptive analyses,
age-adjusted incident IHD hospitalisation rates
(Standard European Population) were calculated for
each year and sex. These rates were depicted graphically,
as were the frequency measures of the remaining
explanatory variables for each year.
The effect of the explanatory variables on incident
IHD morbidity was estimated on the basis of incidence
rates ratios (IRRs) derived from mixed Poisson regres-
sion models of ﬁxed and random effects, with year
being introduced as the random-effect variable, using
the command ‘xtmepoisson’ implemented in Stata, that
ﬁts mixed-effects models for count responses assuming a
Poisson distribution of the data.This approach enables
one to control for temporal autocorrelation and overdis-
persion, measure interannual variability explained by
the preventive measures and minimise the risk of
residual confounding. The dependent variable was the
number of incident hospitalisations in each sex and age
stratum, and the national population ﬁgure of each
stratum was introduced as the exposed population. This
is equivalent to modelling of rates. The explanatory vari-
ables were sequentially introduced, successively obtain-
ing age-adjusted and sex-adjusted estimators and
multivariate estimators. We considered the concurrent
effect across time of the explanatory variables and hospi-
talisation, plus the effect with lags of 1, 2 and 3 years, so
as to take into account the possible latency between
exposure and its effect, and assess the temporality of the
associations.
The effect of drug therapy for control of vascular risk
was analysed for each type of drug (statins, antihyperten-
sive, antiplatelet and antidiabetic drugs), individually
and jointly, using the variable ‘drug use for control of
vascular risk’ obtained by adding together the respective
usages of each type to avoid the strong collinearity that
characterises the consumption of such drugs (correl-
ation coefﬁcients of 0.97 to 0.99). The explanatory vari-
ables categorised in quartiles were included in the
models for dose–response analysis. These models were
used to measure the interannual variability explained by
the variables, calculated as 1 minus the ratio between
the variance of the random term in the complete model
and the variance of the random term in the model
without prevention explanatory variables and in the
model adjusted for age and sex.
Finally, the incidence time series was analysed and
plotted graphically with the aid of Poisson non-
parametric generalised additive models (GAMs) imple-
mented in the mgcv library of the R statistical package
V.2.15.0 (30 March 2012).29 GAM models allow to graph-
ically depict the relationship including smoothing and a
non-parametric ﬁt, with no a priori assumptions on the
actual relationship between response and predictor. As
time is used as the predictor, the result is a smoothed
time series of the response. The rates were modelled
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and smoothed by reference to time, and the smoothed
age-adjusted and sex-adjusted series were depicted
graphically. The explanatory variables were subsequently
included in these models to depict the trends not due
to these variables.
(See technical appendix in supplementary material
for theoretical basis of models and technical details.)
RESULTS
Across the 28 years and 671.5 million person-years of
observation, there were 2 986 834 hospitalisations in
Spain due to IHD; and of these, 1 441 980 (66.7% men
and 33.3% women), accounting for 48.28% of the total,
were classiﬁed as incident. The mean age at admission
was 65.9±12.8 years, with a higher frequency in the 60–
74-year age group (41.9%). Diagnosis at discharge was
acute infarction in 55%, unstable angina in 14.7% and
stable angina in 30.3% of cases. Women’s mean age was
5 years older (p<0.001) than men, and the over 74-year
age group was far more frequent among women than
among men (data not shown).
The annual age-adjusted incident IHD hospitalisation
rates per 100 000, which are depicted graphically in
ﬁgure 1, show a rise from 1982 to 1996, a sharp inﬂec-
tion in 1997 and a subsequent cumulative decrease of
52% until 2009 (53.5% and 49.6% in men and women,
respectively). The decline was constant throughout the
period, with a slight increase in 2000, coinciding with
the change in the deﬁnition of IHD. The distribution by
sex of the incidence rates changed across the study
period, with a decrease in the male/female ratio from
3.3 to 2.4.
Of the total study period (1982–2009), data on indica-
tors of cardiovascular disease prevention (prevalence of
smoking, prevalence of obesity and overweight and use
of drug therapy for control of vascular risk) were avail-
able for the period 1996–2006. These years witnessed a
rise in the use of statins (948.9%) and antihypertensive
(95.4%), antiplatelet (105%) and antidiabetic drugs
(142%) and a decline in smoking prevalence (6.8% in
women and 23.8% in men). Prevalence of obesity
increased by 40% (table 1 and ﬁgure 1).
Consumption of statins and antihypertensive, antipla-
telet and antidiabetic drugs, individually considered, dis-
played an inverse and statistically signiﬁcant relationship
with incident IHD hospitalisation rates in models
adjusted for age, sex and prevalences of smoking,
obesity and overweight (table 2), and this association
became progressively greater when growing lags were
taken into account. Similarly, the use of drugs consid-
ered jointly was inversely associated (IRR 0.97, 95% CI
0.97 to 0.98) with IHD incidence. The greater magni-
tude of the effect of drug use when considered individu-
ally rather than jointly should not be construed as a
discrepancy: instead, this is attributable to the difference
in scale and to drug associations and the lack of adjust-
ment among the individual drug usages due to
collinearity. In contrast, prevalence of smoking, obesity
and overweight was positively associated with incidence
of hospitalisation due to IHD. In the models in which
adjustment was additionally made for prevalences of
arterial hypertension, hypercholesterolaemia and dia-
betes mellitus, and for the number of physically available
beds in intensive and coronary care units, the above
associations were not substantially modiﬁed, that is, the
effect of frequency of smoking was not modiﬁed, the
effect of frequency of obesity and overweight was slightly
attenuated and the inverse association with drug use was
slightly accentuated, when the respective types of drugs
were considered individually and when they were consid-
ered jointly.
Furthermore, these associations displayed a statistically
signiﬁcant dose–response relationship in the models
adjusted for sex, age, the variables in the table and year
as a random-effect variable (table 3): whereas the IRR of
smoking prevalence in the fourth versus the ﬁrst quartile
was 1.46 (95% CI 1.42 to 1.50) and the IRRs for preva-
lence of obesity and overweight were 1.80 (1.78 to 1.83)
and 1.58 (1.55 to 1.60), respectively, and the IRR for car-
diovascular disease prevention drug therapy was 0.57
(0.51 to 0.63). The linear trend was statistically signiﬁcant
for all four variables. The protective effect of cardiovascu-
lar disease prevention drug therapy was slightly attenu-
ated when the growing lags between exposure and effect
were taken into account (IRR lag 0=0.57 (0.51 to 0.63)/
IRR lag 3=0.61 (0.57 to 0.66)). Similarly, while the associ-
ation with prevalence of overweight was attenuated over
time, the association was not modiﬁed when the growing
lags between exposure and effect for prevalences of
obesity and smoking habit were taken into account.
The interannual variability in hospitalisation rates
explained by the models considering the four variables
simultaneously (continuous scale) was: 92% for no lag
between exposure and effect; 95% for a lag of 1 year;
97% for a lag of 2 years and 94% for a lag of 3 years
(data not shown in tables). The proportion of variability
in annual rates explained by prevention variables raised
from 92%, with respect to the empty model, to 97%
when calculated with respect to the model adjusted by
age and sex, thus meaning a 5% variability in hospitalisa-
tion rates due to changes in age-sex population structure
from 1996 to 2006.
Finally, ﬁgure 2 describes the time series of incidence
analysed using Poisson non-parametric generalised addi-
tive models. The left plot displays the downward trend in
the annual age-adjusted and sex-adjusted incidence
rates, which shows very narrow CI because of the very
large size of the study population. This downward trend
disappeared after additionally adjusting for the four
explanatory variables (ﬁgure 2, right plot), which shows
that the decrease was due to the effect of these same
variables. From 2004 onwards, however, the declining
trend remained in evidence even after adjustment was
made for use of preventive drug therapy and prevalence
of smoking, obesity and overweight.
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DISCUSSION
The results show that, after decades of continuous rises,
hospitalisation due to incident IHD in the Spanish adult
population fell after 1997, a drop that was associated
with the decline in smoking and, in equal measure, with
the increase in pharmacological treatment of vascular
risk. This decrease in IHD hospitalisation rates could
have been even greater, had it not been for the fre-
quency of excessive weight, which not only failed to
decline but actually rose. Overall, the factors analysed
accounted for over 90% of the decrease in incident IHD
hospitalisation rates. The decline occurred despite the
increased sensitivity of diagnostic tests and the ensuing
change in the IHD-deﬁnition criteria.30
The accuracy of the results is reinforced because the
associations show a strong dose–response relationship
and a correct temporality, with the effect being main-
tained in response to growing lags between exposure
and disease. The associations found are biologically
plausible, since the role of smoking in the aetiology of
Figure 1 Annual trends in explanatory variables and incident ischaemic heart disease hospitalisation rates.
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coronary disease and the effect of drugs on vascular risk
have been sufﬁciently proved by in vitro studies and clin-
ical trials. Finally, the results are in line with: what has
been published with respect to the decreases in IHD
mortality15–21 and hospital morbidity recorded in other
countries22–26; the decline in the incidence of
smoking-related diseases such as asthma and lung
cancer in Spain28; the reduction in mean population
levels of serum cholesterol and systolic blood pressure21
and the increase in the rates of detection, treatment and
control of vascular risk as documented by cross-sectional
studies on the Spanish population.31
The study shows the success of the smoking control
strategies implemented in the 1990s,32 based on legisla-
tive measures targeted at restricting the sale, raising the
price and placing limitations on the advertising of cigar-
ettes, information programmes about smoking-related
risks and antismoking campaigns. These measures were
followed by a considerable decline in the frequency of
active smoking, principally among light and moderate
smokers.28 The most recent legislative measures, aimed
at preventing passive smoking, have not achieved such a
marked decrease in active smoking prevalence. Our
results suggest, however, that part of the decline in IHD
Table 1 Annual trends in explanatory variables in Spanish general population
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Proportion (%) Smokers 31.9 32.0 31.8 31.6 31.4 31.2 29.8 28.4 27.9 27.8 27.6
Proportion (%) Obesity 15.1 16.1 16.1 16.2 16.3 16.3 16.2 16.0 16.7 17.3 17.9
Proportion (%) Overweight 41.0 40.3 40.6 41.0 41.4 41.8 41.2 40.6 40.7 40.7 40.8
Drugs for control of vascular risk
Number of Defined Daily Doses* per
1000 inhabitants per day (×10). Total
171.5 185.6 204.9 227.7 253.8 279.2 303.0 329.7 359.6 377.7 412.3
Statins 7.8 9.4 14.3 19.7 24.4 30.4 38.0 48.7 60.1 69.2 81.3
Antihypertensive drugs 119.2 127.6 136.6 148.4 163.8 175.7 186.9 197.1 210.2 215.7 232.9
Antidiabetic drugs 27.0 28.9 32.3 35.6 39.1 43.2 46.0 48.9 51.7 53.3 55.7
Antiplatelet drugs 17.5 19.6 21.7 24.0 26.6 29.9 32.2 35.0 37.6 39.5 42.4
DDD: number of doses (adult average maintenance dose per day) prescribed and sold in the National Health System.
Table 2 Effect of prevalence of smoking habit, obesity, overweight and use of cardiovascular disease prevention drug
therapy on annual incident ischaemic heart disease hospitalisation rates 1996–2006
Lag0 Lag1 Lag2 Lag3
IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
Adjustment for age, sex, year (random variable) and specified variables
Smokers (%) 1.02 (1.01 to 1.02) 1.02 (1.02 to 1.02) 1.02 (1.02 to 1.02) 1.02 (1.02 to 1.02)
Obesity (%) 1.05 (1.04 to 1.05) 1.05 (1.05 to 1.05) 1.05 (1.05 to 1.05) 1.06 (1.05 to 1.06)
Overweight (%) 1.04 (1.04 to 1.04) 1.04 (1.04 to 1.04) 1.03 (1.03 to 1.04) 1.03 (1.03 to 1.03)
Drug use (×10 DHDs*)† 0.97 (0.97 to 0.98) 0.97 (0.97 to 0.97) 0.97 (0.97 to 0.97) 0.97 (0.96 to 0.97)
Statins† 0.92 (0.91 to 0.93) 0.91 (0.90 to 0.92) 0.90 (0.88 to 0.91) 0.87 (0.85 to 0.90)
Antihypertensive drugs† 0.95 (0.94 to 0.95) 0.94 (0.94 to 0.95) 0.94 (0.94 to 0.94) 0.93 (0.93 to 0.94)
Antidiabetic drugs† 0.81 (0.79 to 0.83) 0.81 (0.79 to 0.83) 0.80 (0.79 to 0.81) 0.78 (0.77 to 0.79)
Antiplatelet drugs† 0.77 (0.76 to 0.79) 0.77 (0.75 to 0.79) 0.75 (0.74 to 0.77) 0.72 (0.70 to 0.74)
Multivariate adjustment‡
Smokers (%) 1.01 (1.01 to 1.01) 1.02 (1.01 to 1.02) 1.02 (1.02 to 1.02) 1.02 (1.02 to 1.02)
Obesity (%) 1.03 (1.03 to 1.03) 1.03 (1.03 to 1.04) 1.03 (1.03 to 1.04) 1.03 (1.03 to 1.04)
Overweight (%) 1.03 (1.03 to 1.03) 1.03 (1.03 to 1.03) 1.03 (1.02 to 1.03) 1.03 (1.03 to 1.03)
Drug use (×10 DHDs*)† 0.96 (0.96 to 0.97) 0.96 (0.96 to 0.97) 0.96 (0.96 to 0.96) 0.96 (0.96 to 0.96)
Statins† 0.90 (0.89 to 0.91) 0.89 (0.88 to 0.90) 0.87 (0.86 to 0.89) 0.85 (0.83 to 0.87)
Antihypertensive drugs† 0.92 (0.91 to 0.93) 0.92 (0.91 to 0.93) 0.92 (0.92 to 0.93) 0.92 (0.92 to 0.93)
Antidiabetic drugs† 0.73 (0.68 to 0.77) 0.74 (0.71 to 0.77) 0.75 (0.73 to 0.77) 0.75 (0.74 to 0.75)
Antiplatelet drugs† 0.70 (0.66 to 0.73) 0.70 (0.67 to 0.73) 0.70 (0.68 to 0.71) 0.68 (0.67 to 0.70)
Models for exposure–effect lags of 0, 1, 2 and 3 years.
*DHDs: Number of Defined Daily Doses per 1000 inhabitants per day.
†Not adjusted among themselves because collinearity.
‡Adjusted for variables specified in the table plus age, sex, year of discharge as a random-effect variable, prevalence (%) of arterial
hypertension, prevalence (%) of hypercholesterolaemia, prevalence (%) of mellitus diabetes and the number of hospital beds in intensive care
and coronary care units.
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incidence in the recent years of the study is not
accounted for by the factors analysed, indicating, in
turn, that this may be due to the decline in passive
smoking, resulting not only from the cumulative reduc-
tion in active smoking itself in the years preceding the
entry into force of these measures, but also from the
direct impact of the ﬁrst Antismoking Act. Different
studies undertaken in Spain33 34 and other countries12 13
have shown the effect on IHD mortality and morbidity
of a legal ban on smoking in the workplace.
The results support a primary prevention strategy
based on pharmacological control of vascular risk.
Evidence of the effectiveness of this strategy at a popula-
tion level, which implies the mass use of medication, is
especially important in an adverse economic context,
and more so when the use of drugs for cardiovascular
Table 3 Dose–response analysis of the effect of prevalence of smoking habit, obesity, overweight and use of cardiovascular
disease prevention drug therapy on incident ischaemic heart disease hospitalisation rates
Lag0 Lag1 Lag2 Lag3
IRR* 95% CI IRR* 95% CI IRR* 95% CI IRR* 95% CI
Smokers (%)
1st quartile 1.00 1.00 1.00 1.00
2nd quartile 0.92 (0.91 to 0.93) 0.91 (0.90 to 0.93) 0.92 (0.91 to 0.94) 0.93 (0.91 to 0.94)
3rd quartile 1.23 (1.21 to 1.25) 1.21 (1.19 to 1.23) 1.20 (1.18 to 1.22) 1.18 (1.15 to 1.20)
4th quartile 1.46 (1.42 to 1.50) 1.48 (1.44 to 1.52) 1.50 (1.46 to 1.55) 1.49 (1.45 to 1.54)
P trend <0.001 <0.001 <0.001 <0.001
Obesity (%)
1st quartile 1.00 1.00 1.00 1.00
2nd quartile 1.46 (1.44 to 1.47) 1.45 (1.43 to 1.46) 1.34 (1.33 to 1.36) 1.32 (1.30 to 1.33)
3rd quartile 1.71 (1.69 to 1.73) 1.65 (1.63 to 1.67) 1.53 (1.51 to 1.55) 1.48 (1.46 to 1.50)
4th quartile 1.80 (1.78 to 1.83) 1.82 (1.79 to 1.85) 1.75 (1.73 to 1.79) 1.86 (1.78 to 1.90)
P trend <0.001 <0.001 <0.001 <0.001
Overweight (%)
1st quartile 1.00 1.00 1.00 1.00
2nd quartile 1.23 (1.22 to 1.24) 1.21 (1.19 to 1.22) 1.14 (1.13 to 1.16) 1.06 (1.05 to 1.08)
3rd quartile 1.41 (1.39 to 1.43) 1.35 (1.33 to 1.37) 1.30 (1.28 to 1.31) 1.22 (1.20 to 1.24)
4th quartile 1.58 (1.55 to 1.60) 1.50 (1.47 to 1.52) 1.43 (1.41 to 1.45) 1.33 (1.31 to 1.36)
P trend <0.001 <0.001 <0.001 <0.001
Use of drugs (×10 DHDs†)
1st quartile 1.00 1.00 1.00 1.00
2nd quartile 0.85 (0.76 to 0.93) 0.87 (0.80 to 0.94) 0.83 (0.78 to 0.88) 0.84 (0.78 to 0.90)
3rd quartile 0.71 (0.65 to 0.79) 0.73 (0.68 to 0.79) 0.71 (0.67 to 0.75) 0.70 (0.65 to 0.75)
4th quartile 0.57 (0.51 to 0.63) 0.59 (0.55 to 0.64) 0.62 (0.58 to 0.66) 0.61 (0.57 to 0.66)
P trend <0.001 <0.001 <0.001 <0.001
Models for exposure–effect lags of 0, 1, 2 and 3 years.
*IRR adjusted for variables specified in the table plus age, sex and year of discharge as a random-effect variable. Four independent models,
each including the variable of interest on a categorical scale adjusted for the others on a continuous scale.
†DHDs: Number of Defined Daily Doses per 1000 inhabitants per day.
DHD, defined daily doses; IRRs, incidence rate ratios.
Figure 2 Time series of
incidence analysed using
non-parametric generalised
additive models. Left plot:
smoothed series adjusted for age
and sex. Right plot: smoothed
series adjusted for age, sex,
prevalence of smoking, obesity
and overweight, and use of
cardiovascular disease prevention
drug therapy. Solid lines represent
the incidence rate ratios (IRRs)
and dashed lines are the upper
and lower limits of its 95% CI.
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disease prevention in healthy persons has been the
subject of controversy.35 Speciﬁcally, in the case of the
various statins, meta-analyses of clinical trials have
yielded contradictory results,36–40 with some authors
being of the opinion that it is preferable to change the
lifestyles of these patients. While this study does not
purport to assess the clinical effect of these drugs, its
results, nonetheless, show a statistically signiﬁcant
decrease in the age-adjusted and sex-adjusted hospital-
isation rate associated with the use of statins and hyper-
tensive, antiplatelet and antidiabetic drugs. Although
the presence of strong collinearity ruled out any analysis
of the independent effect of each of these drugs with
adjustment for remainder, their use considered jointly
did show a strong protective effect, regardless of the
effect of sex, age, smoking prevalence and excessive
weight, a ﬁnding in line with the consideration that vas-
cular risk is multifactorial and cannot be corrected by
controlling the respective risk factors in isolation.7 The
appropriate balance between economic and health
objectives by policies aimed at reducing pharmaceutical
costs, such as those fostering the use of generic drugs or
a gradual reduction in proﬁt margins for producers and
distributors,41 has been a decisive factor in this public
health success. However, recent studies reveal that there
is still much room for improvement in the detection,
treatment and control of vascular risk.31
In contrast with smoking and control of vascular risk,
prevalences of overweight and obesity, positively asso-
ciated with incident IHD hospitalisation rates, increased
across the study period, indicating that prevention based
on promoting a healthy diet and physical exercise and
changing obesogenic lifestyles is proving inadequate or
ineffective, probably because the effects of these policies
will only be seen in the longer term.10 Without ignoring
smoking prevention or therapeutic control of vascular
risk, our results indicate that, from a public health
stance, treatment and prevention of excess weight
should be made a priority. Community interventions
aimed at changing the prevalence of obesity and seden-
tarism are multidisciplinary, going beyond the strict
scope of healthcare and involving multiple levels, such
as education, the food sector, town planning and admin-
istration, provision of sports facilities, transport policy,
etc.11 Moreover, with the change of lifestyles, many treat-
ments could be avoided—and in this respect, our sympa-
thies are with those who advocate this—but, until such a
time as a cost-effective means of changing the preva-
lence of obesity and sedentarism becomes available, the
use of vascular prevention drug therapy is an inevitable
strategy.
In the correct interpretation of the results of this
study, some limitations must be borne in mind. First, this
study was based on health indicators and targeted at the
assessment of public health; its results should not be
extrapolated to the clinical sphere, that is, to the clinical
management of individual patients, and are thus not
interpretable as outcomes of clinical or intervention
trials, even though they may nuance the latter to the
extent they provide an illustration of their external valid-
ity. Second, the results are exclusively applicable to cases
of hospitalised incident IHD; having said this, however,
the possibility that the decline in hospitalisations might
be due to increases in preadmission mortality can be
conclusively ruled out because mortality rates due to
sudden death or poorly deﬁned causes not only
decreased across the study period but they actually
decreased to a greater extent.2 Errors of measurement
that are inherent in the ecological design and limit
causal inference are of little relevance in this study, in
view of the fact that, in all the factors considered, causal-
ity was clearly shown. Identiﬁcation of incident cases was
based on an estimate but the method used was validated,
with high sensitivity and speciﬁcity values being
obtained. What is more, the proportion of cases of acute
infarction with previous clinical history in our series
(26.6%) agrees with the results of the PRIAMHO II
Registry,42 in which 24% of cases were shown to have a
history of previous infarction or revascularisation.
The remaining potential study limitations stem from
the nature of the available data and, were they to have
some impact, would in all cases bias the results towards
the null hypothesis and so tend to underestimate the
effect. With respect to the exposure data studied, these
were drawn from a self-report questionnaire without any
objective measures of smoking, weight and height; and,
while self-reported smoking data are regarded as valid,
those on obesity and overweight may be underestimated.
The data relating to drug use refer to total use: these
drugs are prescribed not only for primary prevention,
but also for secondary prevention and treatment of
other conditions, such as arrhythmias and heart failure.
Nevertheless, the frequency of these diseases is inﬁnitely
lower than the prevalence of vascular risk in the general
adult population, and is, indeed, almost negligible in
comparison. At all events, the error would, yet again,
tend more towards overestimating exposure and, by
extension, underestimating the effect. Finally, speciﬁc
dietary factors (ie, ﬁsh, vegetables or alcoholic bev-
erages), nutritional factors (ie, fats) and physical activity
factors were not analysed for reasons of parsimony;
instead, the frequency of obesity and overweight was
used as an indicator of quality of diet and physical activ-
ity as a whole.
In conclusion, after decades of continuous rises, inci-
dence of IHD hospitalisation fell from 1997 onwards, a
decline that was associated with the decrease in smoking
and, in equal measure, with the increase in vascular risk
drug therapy. The cumulative decline of 52% over
13 years might have been even greater if there had not
been a concomitant increase in the prevalence of exces-
sive weight, also associated with incidence. These results
indicate that current IHD primary prevention strategies
have been effective at a population level, thanks to an
appropriate balance between ﬁnancial and health goals,
something that should be left intact despite the current
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economic crisis. Future strategies should lay special
stress on the prevention and treatment of excessive
weight.
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